Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2019-01-04 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-01-04 English
4
Director's Dealing
2019-01-04 English
4
Director's Dealing
2019-01-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 4, 2019. It reports "Other Events" under Item 8.01, specifically a press release providing an update on the company's business and strategic priorities. The document is short (3237 characters) and primarily references an attached press release (Exhibit 99.1). There are no financial statements or detailed financial data included. The content is an announcement of a business update rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 2, 2019, reporting the termination of material definitive agreements between Mersana Therapeutics, Inc. and Millennium Pharmaceuticals, Inc. It details the termination notices and the winding down of collaboration agreements. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The content is a regulatory announcement about a material contract termination, which fits the category of a general regulatory filing. The document length is 4855 characters, which is not extremely short, but the content is clearly a current report on a material event rather than a full financial report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-01-04 English
4
Director's Dealing
2018-12-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.